12:00 AM
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Pacritinib: Additional Phase I data

Additional data from an open-label, dose-escalation Phase I trial in 34 patients with relapsed or refractory NHL or Hodgkin's lymphoma showed that once-daily doses of 100-600 mg oral pacritinib led to a median progression-free survival (PFS) of 120 days and a median overall survival (OS) of...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >